Pomella®: New Study investigates gut derived metabolites urolithins

A new pharmacokinetics study was conducted at the University of Mississippi. Researchers investigated the metabolism of Pomella® extract with emphasis on the major polyphenol, punicalagin, and the gut derived metabolites urolithin A and B.¹

The study showed that punicalagin rapidly metabolised to ellagic acid which then rapidly absorbed and conjugated after oral administration. The conjugated ellagic acid exposure was approximately 5-8x higher than unconjugated EA for both dose groups, while urolithin A appeared in the bloodstream at a delayed rate, starting approximately 8 hours after dosing. The results support the gut microbiota-mediated metabolism of ellagitannins, specifically punicalagins to ellagic acids and then to urolithins.

In the study, subjects were given 250mg or 1000mg of Pomella® standardised to contain not less than 30% punicalagins, and not less than 50% polyphenols. Plasma samples were collected over a 48hr period.

Given the recent interest in specific gut microbiota and their roles in metabolising ellagitannins to UA and their association to positive health, this study supports the polyphenol capability in Pomella®.

Pomella® Pomegranate Extract is a scientifically researched, clean-label, plant-based ingredient offering potent antioxidant properties that support a wide variety of applications, including gut health, beauty from within, cardiovascular, oral health and much more.

For more information visit our Pomella® dedicated page or contact us.

_Reference:

_{1) Wang et al-2023-Journal of Pharmaceutical and Biomedical Analysis: Development of a liquid chromatography-tandem mass spectrometry (LC–MS/MS) method for characterizing pomegranate extract pharmacokinetics in humans. DOI: 10.1016/j.jchromb.2020.122278.}